Raymond James Financial Reiterates “Market Perform” Rating for Bath & Body Works (NYSE:BBWI)

Bath & Body Works (NYSE:BBWI)‘s stock had its “market perform” rating reaffirmed by Raymond James Financial in a research report issued to clients and investors on Wednesday,Benzinga reports.

Several other brokerages have also recently issued reports on BBWI. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $26.00 price objective on shares of Bath & Body Works in a report on Monday, October 6th. Wall Street Zen cut shares of Bath & Body Works from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Bath & Body Works in a research report on Wednesday, October 8th. Barclays dropped their price objective on shares of Bath & Body Works from $32.00 to $28.00 and set an “equal weight” rating for the company in a research note on Monday, October 20th. Finally, UBS Group reduced their target price on shares of Bath & Body Works from $36.00 to $32.00 and set a “neutral” rating on the stock in a report on Friday, August 29th. Ten research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $38.18.

Bath & Body Works Stock Down 2.2%

BBWI opened at $21.93 on Wednesday. The company has a market capitalization of $4.52 billion, a PE ratio of 6.51, a price-to-earnings-growth ratio of 0.86 and a beta of 1.53. The firm has a 50-day simple moving average of $26.01 and a two-hundred day simple moving average of $28.70. Bath & Body Works has a 52 week low of $21.82 and a 52 week high of $41.87.

Bath & Body Works (NYSE:BBWI) last issued its earnings results on Thursday, August 28th. The company reported $0.37 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.37. Bath & Body Works had a negative return on equity of 48.43% and a net margin of 9.88%.The firm had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.55 billion. During the same period in the previous year, the firm posted $0.37 earnings per share. The business’s revenue was down .8% compared to the same quarter last year. Bath & Body Works has set its Q3 2025 guidance at 0.370-0.45 EPS. FY 2025 guidance at 3.350-3.600 EPS. As a group, sell-side analysts expect that Bath & Body Works will post 3.3 earnings per share for the current year.

Hedge Funds Weigh In On Bath & Body Works

Several hedge funds have recently added to or reduced their stakes in the company. First Horizon Corp purchased a new stake in shares of Bath & Body Works in the third quarter worth approximately $29,000. Stonehage Fleming Financial Services Holdings Ltd purchased a new position in shares of Bath & Body Works during the second quarter worth approximately $33,000. SVB Wealth LLC bought a new stake in shares of Bath & Body Works during the first quarter valued at approximately $35,000. Geneos Wealth Management Inc. boosted its holdings in shares of Bath & Body Works by 217.7% in the first quarter. Geneos Wealth Management Inc. now owns 1,169 shares of the company’s stock valued at $35,000 after purchasing an additional 801 shares during the period. Finally, Parallel Advisors LLC grew its stake in Bath & Body Works by 63.3% in the second quarter. Parallel Advisors LLC now owns 1,241 shares of the company’s stock worth $37,000 after purchasing an additional 481 shares in the last quarter. 95.14% of the stock is currently owned by institutional investors.

About Bath & Body Works

Bath & Body Works, Inc is a specialty retailers and home to America’s Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap.